Med Cause - Medcause.com
Popular

In 2022, there were almost 20 million new cases of cancer as well as 9.7 million deaths from cancer, according to a study published online April 4 in CA: A Cancer Journal for Clinicians.

Freddie Bray, Ph.D., from the International Agency for Research on Cancer in Lyon, France, and colleagues present global cancer statistics for 2022 by world region.
The researchers found there were about 20 million new cases of cancer in 2022, including nonmelanoma skin cancers, as well as 9.7 million deaths from cancer. These estimates suggest that about one in five men or women develop cancer in a lifetime, and one in nine men and one in 12 women die from cancer.
In 2022, lung cancer was the most frequently diagnosed cancer, responsible for close to 2.5 million new cases (12.4 percent of cancers globally), followed by cancers of the female breast, colorectum, prostate, and stomach (11.6, 9.6, 7.3, and 4.9 percent, respectively). The leading cause of cancer death was lung cancer, with an estimated 1.8 million deaths (18.7 percent), followed by colorectal, liver, female breast, and stomach cancers (9.3, 7.8, 6.9, and 6.8 percent, respectively).
In women and men, the most frequent cancers were breast and lung cancer (both cases and deaths). Across world regions, incidence rates varied from fourfold to five-fold for men and women.
“The overall scale of cancer and the diversity of cancer profiles by world region and human development level reemphasize the need for a global escalation of targeted cancer control measures,” the authors write.

More information:
Freddie Bray et al, Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA: A Cancer Journal for Clinicians (2024). DOI: 10.3322/caac.21834

Copyright © 2024 HealthDay. All rights reserved.

Citation:
Statistics presented for global cancer incidence, deaths in 2022 (2024, April 6)
retrieved 7 April 2024
from

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.

Share this article
Shareable URL
Prev Post
Next Post
Leave a Reply

Your email address will not be published. Required fields are marked *

Read next
Credit: Pixabay/CC0 Public Domain Experts at University of Michigan Health Rogel Cancer Center have conducted…
Trial schema of immune-checkpoint inhibition in retroperitoneal DDLPS and extremity/truncal UPS. Credit: Nature…
Credit: Pixabay/CC0 Public Domain A study led by UCLA Health Jonsson Comprehensive Cancer Center researchers…
Credit: Pixabay/CC0 Public Domain A new paper in Biology Methods & Protocols indicates that it may soon be…
Need Help?